Bebtelovimab Frequently Asked Questions

Your body naturally produces proteins called antibodies to fight infections such as SARS-CoV-2, the virus that causes COVID-19. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens, such as viruses. Monoclonal antibodies prevent and treat COVID-19 by targeting the spike protein of SARS-CoV-2 to block the virus’ attachment and entry into human cells. Bebtelovimab is a COVID-19 monoclonal antibody.

The FDA granted EUA (Emergency Use Authorization) for the bebtelovimab COVID-19 therapy for adults and children (age 12 years and older weighing at least 40 kg) with mild to moderate COVID-19 symptoms and who are at high risk for progression to severe COVID-19.

Yes, a prescription from a qualified healthcare provider is required to be treated with bebtelovimab.

The U.S. Department of Health and Human Services (HHS) has agreed to purchase up to 600,000 patient courses of bebtelovimab and we will make the product available across the country to state and territorial health departments at no cost beginning on Monday, Feb. 14, 2022. While the drug is free to eligible individuals, there may be an associated administration fee.

HHS determines allocations to state and territorial health departments using a disease-based methodology that incorporates COVID-19 case counts and hospitalizations within jurisdictions.

The ordering portal for bebtelovimab opens Feb. 14, 2022. State and territorial health departments must first identify receiving sites before ordering can take place. Jurisdictions can then order product through the HHS Health Partners Ordering Portal (HPOP) for shipment to receiving sites.